Carregant...

A109 PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN THE CROHN’S DISEASE CLINICAL DEVELOPMENT PROGRAM

BACKGROUND: Ustekinumab (UST) has been approved for moderate to severe Crohn’s Disease (CD) in adult patients (pts). While no adverse developmental outcomes (pre-& postnatal) were observed in animal studies of UST, limited data exist, including previously reported outcomes in psoriasis (PsO) pts...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Can Assoc Gastroenterol
Autors principals: Scherl, E, Jacobstein, D, Murphy, C, Ott, E, Gasink, C, Baumgart, D C, Abraham, B
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!